Ambrx Biopharma Inc AMAM:NYSE

Last Price$8.95NYSE Previous Close - Last Trade as of 7:00PM ET 12/03/21
NYSE 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$8.18 (2)
Ask (Size)$16.20 (2)
Day Low / HighN/A - N/A
Volume8.5 K
 

Read more news Recent News

Ambrx Biopharma Starts Dosing in Mid-Stage Clinical Study of ARX788 for HER2-Positive Metastatic Breast Cancer
3:43PM ET 11/04/2021 MT Newswires

Ambrx Biopharma (AMAM) said Thursday that dosing has begun in its mid-stage clinical study of ARX788, an anti-HER2 antibody drug conjugate, in patients...

Ambrx Biopharma Starts Dosing Patients with Solid Tumors in Early-Stage ARX517 Trial
11:50AM ET 8/03/2021 MT Newswires

Ambrx Biopharma (AMAM) on Tuesday said that dosing has begun in the phase 1 study of its drug candidate ARX517 in subjects with prostate specific membrane...

--BofA Securities Starts Ambrx Biopharma at Buy With $26 Price Target
7:22AM ET 7/13/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Cowen Initiates Coverage on Ambrx Biopharma With Outperform Rating
6:36AM ET 7/13/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business Description
Number of EmployeesN/A
Recent SEC Filing11/22/20216-K

Company Highlights

Price Open$9.07
Previous Close$9.25
52 Week Range$8.40 - 22.87
Market Capitalization$344.2 M
Shares Outstanding38.5 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings AnnouncementN/A

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per ShareN/A
Beta vs. S&P 500N/A
RevenueN/A
Net Profit MarginN/A
Return on EquityN/A

Analyst Ratings as of 11/03/2021

Buy
2
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset